Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Author： Soverini Simona   De Benedittis Caterina   Papayannidis Cristina   Paolini Stefania   Venturi Claudia   Iacobucci Ilaria   Luppi Mario   Bresciani Paola   Salvucci Marzia   Russo Domenico   Sica Simona   Orlandi Ester   Intermesoli Tamara   Gozzini Antonella   Bonifacio Massimiliano   Rigolin Gian Matteo   Pane Fabrizio   Baccarani Michele   Cavo Michele   Martinelli Giovanni  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|7|1002-1009

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.7, 2014-04, pp. : 1002-1009

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia

By Jeha Sima   Coustan-Smith Elaine   Pei Deqing   Sandlund John T.   Rubnitz Jeffrey E.   Howard Scott C.   Inaba Hiroto   Bhojwani Deepa   Metzger Monika L.   Cheng Cheng   Choi John K.   Jacobsen Jeffrey   Shurtleff Sheila A.   Raimondi Susana   Ribeiro Raul C.   Pui Ching-Hon   Campana Dario  

Cancer, Vol. 120, Iss. 10, 2014-05 ,pp. : 1514-1519

Blackwell Publishing

Access to resources Recommend Favorite

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

By Soverini Simona   Martinelli Giovanni   Rosti Gianantonio   Iacobucci Ilaria   Baccarani Michele  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1271-1284

Future Medicine

Access to resources Recommend Favorite

BCR-ABL mutations and resistance to imatinib mesylate in Ph+ leukaemia

By  

Inpharma, Vol. 1, Iss. 1325, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

By Carpiuc Kimbach T   Stephens Jennifer M   Botteman Marc F   Feng Weiwei   Hay Joel W  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 16, 2007-11 ,pp. : 2775-2787

Informa Healthcare

Access to resources Recommend Favorite

Imatinib: In Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

By Cross Sarah A.   Lyseng-Williamson Katherine A.  

Drugs, Vol. 67, Iss. 17, 2007-01 ,pp. : 2645-2654

Adis International

Access to resources Recommend Favorite